Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Total Current Liabilities (2016 - 2022)

Edesa Biotech's Total Current Liabilities history spans 10 years, with the latest figure at $5.7 million for Q2 2022.

  • For Q2 2022, Total Current Liabilities rose 475.24% year-over-year to $5.7 million; the TTM value through Jun 2022 reached $5.7 million, up 475.24%, while the annual FY2021 figure was $1.5 million, 4.65% down from the prior year.
  • Total Current Liabilities for Q2 2022 was $5.7 million at Edesa Biotech, up from $3.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $5.7 million in Q2 2022 and bottomed at $183820.0 in Q4 2018.
  • The 5-year median for Total Current Liabilities is $983078.0 (2020), against an average of $1.5 million.
  • The largest annual shift saw Total Current Liabilities tumbled 68.0% in 2018 before it skyrocketed 698.04% in 2021.
  • A 5-year view of Total Current Liabilities shows it stood at $183820.0 in 2018, then soared by 283.07% to $704162.0 in 2019, then rose by 28.71% to $906327.0 in 2020, then skyrocketed by 92.74% to $1.7 million in 2021, then surged by 223.86% to $5.7 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Total Current Liabilities are $5.7 million (Q2 2022), $3.3 million (Q1 2022), and $1.7 million (Q4 2021).